DWPF provided model audit advice to OMERS, Goldman Sachs Asset Management, and AXA-IM on the successful acquisition of Amedes – a German labratory group. The deal is valued at circa. EUR 1.5 Billion (USD 1.8 billion).

The company processes polymerase chain reaction (PCR) tests for the novel coronavirus, as well a wide variety of medical tests for patients, doctors and hospitals, including oncological, genetic, microbiological and pathological tests.

Amedes has annual core earnings of more than EUR 100 Million, operating laboratories at 90 sites in Austria, Belgium and Dubai, as well as Germany, employing about 4,000 staff and treating 450,000 patients a year.